Ionis Pharmaceuticals Shares Owned By Institutions vs. Current Valuation

IONS Stock  USD 37.57  1.02  2.79%   
Based on Ionis Pharmaceuticals' profitability indicators, Ionis Pharmaceuticals may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in July. Profitability indicators assess Ionis Pharmaceuticals' ability to earn profits and add value for shareholders. At this time, Ionis Pharmaceuticals' Price To Sales Ratio is comparatively stable compared to the past year. EV To Sales is likely to gain to 15.52 in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.16 in 2024. At this time, Ionis Pharmaceuticals' Total Other Income Expense Net is comparatively stable compared to the past year. Income Tax Expense is likely to gain to about 33.9 M in 2024, despite the fact that Operating Income is likely to grow to (336 M).
For Ionis Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Ionis Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Ionis Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Ionis Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Ionis Pharmaceuticals over time as well as its relative position and ranking within its peers.
  

Ionis Pharmaceuticals' Revenue Breakdown by Earning Segment

Check out Risk vs Return Analysis.
For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.
Is Ionis Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ionis Pharmaceuticals. If investors know Ionis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ionis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.44)
Earnings Share
(2.67)
Revenue Per Share
5.397
Quarterly Revenue Growth
(0.08)
Return On Assets
(0.08)
The market value of Ionis Pharmaceuticals is measured differently than its book value, which is the value of Ionis that is recorded on the company's balance sheet. Investors also form their own opinion of Ionis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ionis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ionis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ionis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ionis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ionis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ionis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Ionis Pharmaceuticals Current Valuation vs. Shares Owned By Institutions Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Ionis Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Ionis Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Ionis Pharmaceuticals is rated third overall in shares owned by institutions category among related companies. It is rated below average in current valuation category among related companies reporting about  52,938,120  of Current Valuation per Shares Owned By Institutions. Comparative valuation analysis is a catch-all model that can be used if you cannot value Ionis Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Ionis Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Ionis Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Ionis Current Valuation vs. Shares Owned By Institutions

Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.

Ionis Pharmaceuticals

Shares Held by Institutions

 = 

Funds and Banks

+

Firms

 = 
99.14 %
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Ionis Pharmaceuticals

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
5.25 B
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.

Ionis Current Valuation vs Competition

Ionis Pharmaceuticals is rated below average in current valuation category among related companies. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 149.78 Billion. Ionis Pharmaceuticals holds roughly 5.25 Billion in current valuation claiming about 4% of equities under Health Care industry.

Ionis Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Ionis Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Ionis Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Ionis Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Ionis Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-32.6 M-31 M
Operating Income-353.7 M-336 M
Net Loss-366.3 M-348 M
Income Before Tax-334 M-317.3 M
Total Other Income Expense Net101.2 M106.3 M
Income Tax Expense32.3 M33.9 M
Net Loss-366.3 M-348 M
Non Operating Income Net Other184.4 M193.6 M
Net Loss-242.7 M-230.6 M
Interest Income3.1 M2.9 M
Net Interest Income-81.5 M-77.4 M
Change To Netincome118.5 M87.2 M
Net Loss(2.56)(2.43)
Income Quality 0.84  0.88 
Net Income Per E B T 1.10  0.67 

Ionis Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Ionis Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Ionis Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Ionis Pharmaceuticals' important profitability drivers and their relationship over time.

Learn to be your own money manager

Our tools can tell you how much better you can do entering a position in Ionis Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Technical Analysis Now

   

Technical Analysis

Check basic technical indicators and analysis based on most latest market data
All  Next Launch Module

Use Investing Themes to Complement your Ionis Pharmaceuticals position

In addition to having Ionis Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Currency Funds Thematic Idea Now

Currency Funds
Currency Funds Theme
Funds or Etfs investing in a single currency or combination of currencies from different countries in order to replicate respective foreign exchange markets. The Currency Funds theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Currency Funds Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Ionis Pharmaceuticals is a strong investment it is important to analyze Ionis Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ionis Pharmaceuticals' future performance. For an informed investment choice regarding Ionis Stock, refer to the following important reports:
Check out Risk vs Return Analysis.
For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Complementary Tools for Ionis Stock analysis

When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Share Portfolio
Track or share privately all of your investments from the convenience of any device
To fully project Ionis Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Ionis Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Ionis Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.
Potential Ionis Pharmaceuticals investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Ionis Pharmaceuticals investors may work on each financial statement separately, they are all related. The changes in Ionis Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Ionis Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.